Overview

Oxytocin Trial in Prader-Willi Syndrome

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Individuals with Prader-Willi syndrome (PWS) have been found to have a deficit of oxytocin-producing neurons and decreased oxytocin receptor gene function, so the purpose of this study is to determine if oxytocin (OT) administration will improve some of the aspects of Prader-Willi syndrome that are particularly troublesome for children and their families (the insatiable appetite and social behaviors). The research questions are: 1. Does intranasal oxytocin cause any side effects in children with PWS? 2. Does intranasal oxytocin administration alter appetite or behaviors in PWS?
Phase:
Phase 1
Details
Lead Sponsor:
University of Florida
Collaborator:
National Institutes of Health (NIH)
Treatments:
Oxytocin